Preview: Upstream Bio, Inc Set To IPO Tomorrow
Preview: Upstream Bio, Inc Set To IPO Tomorrow
Upstream Bio, Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders and developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin ("TSLP"), a cytokine which is a clinically validated driver of inflammatory response positionedUpstream Bio, Inc (NASDAQ:UPB) IPO will take place October, 11 on the NASDAQ exchange under the ticker UPB.
Upstream Bio, Inc（納斯達克:UPB）的首次公開發行將於10月11日在納斯達克交易所逐筆明細爲UPb下進行。
The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider lock-up period of 180 days ending on April 09, 2025.
該公司以每股15.00美元至17.00美元的預期價格提供股份，內部持股期爲180天，將於2025年4月09日結束。
See also: Benzinga IPO Calendar
參見：Benzinga IPO日曆
About Upstream Bio, Inc
關於Upstream Bio, Inc
Upstream Bio, Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders and developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin ("TSLP"), a cytokine which is a clinically validated driver of inflammatory response positioned
Upstream Bio, Inc是一家臨床階段的生物技術公司，專注於開發治療炎症性疾病，首要關注嚴重呼吸道疾病，並開發verekitug，目前是臨床開發中唯一已知瞄準胸腺基質淋巴造血素（"TSLP"，一種已在臨床驗證中的炎症反應促進因子）受體的拮抗劑。
See also: Benzinga's Most Shorted Stocks
參見：Benzinga的做空集合股
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由Benzinga的自動化內容引擎生成並由編輯審查。
